NeoGraph Analytics
BiotechnologyNorth America2023 – 2032

Global Precision Medicine Market Size, Share and Trends Analysis

Global Precision Medicine market size was $85B in 2023, forecast to reach $226.4B by 2032, growing at 11.5% CAGR.

Revenue, 2023

$85.0B

Forecast, 2032

$226.4B

CAGR, 2024-2032

11.5%

Report Coverage

North America

Code: precision-medicine-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The global precision medicine market was valued at approximately $85 billion in 2023 and is projected to reach $226.4 billion by 2032, growing at a CAGR of 11.5%. Key growth drivers include genomic sequencing cost reductions, AI-driven drug discovery, and rising oncology applications. North America leads with a 42% regional share, while Asia Pacific emerges as the fastest-growing region at 14.2% CAGR. Companion diagnostics and NGS-based platforms dominate the technology landscape.

02

Key Highlights

1

Market projected to reach $226.4B by 2032 at 11.5% CAGR from $85B base

2

Oncology dominates application segment with 40% market share

3

Asia Pacific emerges as fastest-growing region at 14.2% CAGR

03

Market Overview

Market Context

Precision medicine leverages genomic, proteomic, and clinical data to tailor treatments to individual patients. The field has matured from research concept to clinical reality, with companion diagnostics now standard in oncology. Declining sequencing costs and AI-driven analytics are accelerating adoption across therapeutic areas globally.

The precision medicine market is experiencing high growth driven by advances in genomics, AI-powered diagnostics, and targeted therapeutics. Oncology remains the dominant application segment at 40% share. North America leads globally while Asia Pacific shows the fastest expansion.

Market Stage

High growth

Adoption Level

Growing

Key Trends

AI and machine learning integration in genomic data analysisDeclining cost of next-generation sequencing accelerating adoptionGrowing pharmaceutical partnerships with diagnostics companiesExpansion of liquid biopsy technologies for early cancer detection
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 11.5%

Base Year (2023)

$85.0B

Forecast (2032)

$226.4B

CAGR (2024-2032)

11.5%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$85.00B
2024$94.78B
2025$105.67B
2026$117.83B
2027$131.38B
2028$146.49B
2029$163.33B
2030$182.11B
2031$203.06B
2032$226.41B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

The market will nearly triple from $85B to $226.4B over the forecast period, driven primarily by NGS platform adoption, AI integration in clinical workflows, and expanding oncology applications. Asia Pacific's 14.2% CAGR will progressively narrow North America's dominance.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America42.0%10.2%United States
Europe28.0%9.8%Germany
Asia Pacific22.0%14.2%China
Rest of World8.0%11.0%Brazil

North America

#1
Share: 42.0%CAGR: 10.2%

Largest market: United States

Europe

#2
Share: 28.0%CAGR: 9.8%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Rising prevalence of chronic and genetic disorders globally
  • Government initiatives funding personalized therapy research
  • Advancements in genomic sequencing and bioinformatics
06

Market Segmentation

By Technology
Market share distribution across 5 segments
By Technology — market share by segment, in percent.
SegmentShare
Next-Generation Sequencing (NGS)Dominant technology enabling large-scale genomic profiling and variant detection.30.0%
Bioinformatics & AIMachine learning platforms for multi-omics data interpretation and biomarker discovery.25.0%
Companion DiagnosticsFDA-approved tests guiding targeted therapy selection for patients.20.0%
Gene TherapyCRISPR and viral vector-based curative treatment approaches.15.0%
PharmacogenomicsDrug response prediction based on individual genetic profiles.10.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Application
Market share distribution across 6 segments
By Application — market share by segment, in percent.
SegmentShare
OncologyLargest segment driven by targeted therapies and tumor profiling.40.0%
CardiovascularGenetic risk assessment and personalized treatment for heart diseases.20.0%
NeurologicalPrecision approaches for Alzheimer's, Parkinson's, and rare neurological disorders.15.0%
Rare DiseasesWhole-genome sequencing enabling diagnosis of orphan genetic conditions.12.0%
Infectious DiseasesPathogen genomics guiding antimicrobial therapy decisions.8.0%
OthersApplications in immunology, metabolic, and reproductive health.5.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Hospitals & Clinics
  • Research Laboratories
  • Pharmaceutical Companies
  • Diagnostic Centers
07

Regional Analysis

1

North America

Lead: United States
CAGR: 10.2%Share: 42.0%

Market leader driven by advanced healthcare systems, FDA approvals, and major company presence.

2

Europe

Lead: Germany
CAGR: 9.8%Share: 28.0%

Strong growth supported by EU genomics initiatives and precision medicine funding programs.

3

Asia Pacific

Lead: China
CAGR: 14.2%Share: 22.0%

Fastest-growing region due to rising healthcare expenditure, population genomics programs, and expanding biotech infrastructure.

4

Rest of World

Lead: Brazil
CAGR: 11.0%Share: 8.0%

Emerging market with increasing adoption in Latin America and Middle East regions.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
United States
36.0%
+10.0%
Germany
9.0%
+9.5%
China
8.0%
+16.0%
08

Competitive Landscape

R

Roche Holding AG

Switzerland

Leader68B

Dominates companion diagnostics and targeted oncology through Foundation Medicine and cobas sequencing platforms.

Global leader in companion diagnostics and targeted oncology therapies through its Foundation Medicine subsidiary and cobas sequencing systems.

I

Illumina, Inc.

United States

Challenger4.8B

Leads NGS platform innovation with NovaSeq and MiSeq, serving over 4 million patients globally.

Pioneer and dominant force in next-generation sequencing technology, providing comprehensive genomic analysis platforms for research and clinical use.

T

Thermo Fisher Scientific

United States

Follower

Strengthens omics portfolio through Olink Proteomics acquisition, offering broad precision medicine tools.

Also profiled

Q

QIAGEN N.V.

2.1B

Leading provider of sample and assay technologies for molecular diagnostics, enabling precision medicine through companion diagnostics and theranostics.

09

Recent Developments

25
2025Illumina, Inc.

Launched NovaSeq X Plus system achieving $200 whole genome sequencing cost milestone

24
2024Thermo Fisher Scientific

Completed acquisition of Olink Proteomics to strengthen multi-omics precision medicine platform

10

Regulatory Landscape

FDA Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)EU In Vitro Diagnostic Regulation (IVDR) 2022/IVDR compliance requirements
11

Research Methodology

Primary research

  • Expert interviews
  • Surveys

Secondary research

  • Industry reports
  • Company financials

Validation: Triangulation method

12

Strategic Takeaways

Investors

The $85B market growing at 11.5% CAGR offers strong returns in NGS, AI diagnostics, and companion diagnostics segments.

Operators

Prioritize Asia Pacific expansion and AI-powered platform development to capture fastest-growing market segments.

Payers

Expect rising per-patient costs offset by long-term savings from targeted therapies reducing trial-and-error prescribing.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.